患有异酸脱酶突变的急性髓性白血病治疗结果:系统性审查和元分析
Han Qin1, Rui Xu2, Yingchao Yang1
1Department of Blood Transfusion, Dalian Third People's Hospital, Dalian, Liaoning Province, China.
Medicine
|December 10, 2024
概括
异酸脱酶 (IDH) 基因突变会对急性髓性白血病 (AML) 的结果产生不同的影响. IDH1突变可能会使预后恶化,而IDH2突变表现出多种影响,支持个性化的AML治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 异酸脱酶 (IDH) 基因变异与急性髓性白血病 (AML) 的病原发生有关.
- 在AML中IDH突变的预后意义仍然是争论的主题.
- 了解这些突变对于开发向疗法至关重要.
研究的目的:
- 系统地审查和分析关于AMLIDH突变的现有文献.
- 澄清IDH突变对AML患者的预后影响,包括存活和复发.
- 探索基于IDH突变状态的个性化治疗策略的潜力.
主要方法:
- 在七个英语和两个中文数据库中进行了全面的文献搜索.
- 包括调查IDH突变与AML结局之间的关联的研究.
- 聚合危险比率 (HRs) 和95%置信区间 (CI) 计算以评估预后意义.
主要成果:
- 对20项研究的分析表明,IDH突变具有复杂的预后影响.
- IDH突变与整体生存HR的0.76 (95% CI,0.63-0.93) 相关.
- IDH1突变显示出较差无事件存活率的趋势 (HR,1.71;95% CI,1.40-2.08),而IDH2突变的影响不那么明显.
结论:
- 不同的IDH突变亚型 (IDH1与IDH2) 在AML患者中可能会产生不同的预后.
- 这些发现支持了针对AML个性化治疗方法的可行性.
- 对特定的IDH突变进行进一步的研究可以完善风险分层和治疗决策.
更多相关视频
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
3.2K
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.2K
相关概念视频
Electron Transport Chain: Complex I and II
11.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.5K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
iPS Cell Differentiation
2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K
